An additional phase II study queried a more heterogeneous PTCL population, notably including a subset of patients (17%) with absent CD30 expression based on immunohistochemistry (PTCL-NOS: n = 21, AITL: n = 13). Here, TNFRSF8 is linked to angioimmunoblastic T-cell lymphoma.